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Alzheimer’s disease (AD) is considered the “disease of the twenty-ﬁrst century.” With a
10-fold increase in global incidence over the past 100 years, AD is now reaching epidemic
proportions and by all projections, AD patient numberswill continue to rise. Despite intense
research efforts, AD remains a mystery and effective therapies are still unavailable. This
represents an unmet need resulting in clinical, social, and economic problems. Over the
last decade, a new AD research focus has emerged: ATP-binding cassette (ABC) trans-
porters. In this article, we provide an overview of the ABC transporters ABCA1, ABCA2,
P-glycoprotein (ABCB1), MRP1 (ABCC1), and BCRP (ABCG2), all of which are expressed
in the brain and have been implicated in AD.We summarize recent ﬁndings on the role of
these ﬁve transporters in AD, and discuss their potential to serve as therapeutic targets.
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INTRODUCTION
Worldwide,more than 25million patients suffer fromAlzheimer’s
disease (AD), and it is projected that by 2050 this number will
have quadrupled to over 100 million patients (Abbott, 2011). This
development will raise global AD health care costs to unprece-
dented dimensions (Brookmeyer et al., 2007;WHO,2007). Besides
the cost factor, AD is a devastating disease. AD patients decline
mentally and physically and transform from functioning human
beings into helpless dependents, while fading out of life (Mega
et al., 1996).
Currently, few FDA-approved AD medications are on the mar-
ket. Those that are available can cause severe side effects and, if
effective, alleviate disease symptoms up to 6–12months only in
patients with mild to moderate AD (Ellis, 2005; Seltzer, 2007).
Moreover, most patients respond poorly or not at all to therapy.
Thus, there is clearly a great unmet need for new therapies that
target the underlying cause(s) of AD, reverse symptoms, or pre-
vent AD completely. However, despite decades of research efforts,
AD is still a mystery and effective therapies remain unavailable for
millions of patients.
At themolecular level, two proteins – amyloid-β (Aβ) and tau –
are characteristic signatures of AD. Aβ is a small peptide that is
generated through cleavage of amyloid precursor protein (APP);
the most common Aβ isoforms in AD are the neurotoxic peptides
Aβ40 and Aβ42. The physiological function of Aβ is still unclear,
but in healthy individuals Aβ brain levels are low, whereas in AD
patients Aβ levels can be increased up to 100-fold in the brain,
where it aggregates to plaques (Gravina et al., 1995; Hardy and
Selkoe, 2002). Tau proteins are microtubule-associated proteins
that interact with tubulin and promote its insertion into micro-
tubules, thereby modulating stability and ﬂexibility of axonal
microtubules. Phosphorylation of tau, on the other hand, results
in disruption of microtubule organization and structure, and in
AD hyperphosphorylation of tau proteins causes microtubular
collapse and results in the formation of neuroﬁbrillary tangles
inside neurons. BothAβplaques andneuroﬁbrillary tau tangles are
hallmarks of AD pathology and are thought to contribute to neu-
rodegeneration and dementia (Wolozin et al., 1986; Wood et al.,
1986; Hardy and Selkoe, 2002).
Over the last 10 years a new AD research ﬁeld emerged with a
focus on ATP-binding cassette (ABC) transporters at the blood-
brainbarrier and inother cells of theCNS.ABC transporters utilize
ATP tomove their substrates acrossmembranes of organelles, cells,
and tissues. The substrates of ABC transporters involved with AD
include cholesterol, sterols, lipids, peptides,metabolites, and xeno-
biotics including toxins and a large number of therapeutic drugs.
Thus, ABC transporters are an integral part of many physiological
processes and biochemical pathways, and play an important role
in maintaining the body’s homeostasis by extruding metabolites
and limiting uptake of xenobiotics. Only recently have researchers
discovered that ABC transporters also play a critical role in dis-
eases, where processes and pathways involving ABC transporters
are altered. For some ABC transporters – ABCA1, ABCA2, P-gp,
MRP1, and BCRP – such a role is emerging in AD and other CNS
disorders associated with high Aβ brain levels.
If, and how exactly, ABC transporters contribute to AD patho-
physiology is unknown. This lack of understanding provides
opportunities for exciting new discoveries, and more impor-
tantly, holds the promise to unravel details of disease processes
and identify targets that could help in the development of novel
therapeutic strategies for AD. In this review, we summarize cur-
rent knowledge about ABCA1, ABCA2, P-glycoprotein (ABCB1),
MRP1 (ABCC1), and BCRP (ABCG2) in AD, and discuss their
potential as therapeutic targets.
ABCA1 AND ABCA2
BACKGROUND
ABCA1 andABCA2 are prototypicmembers of theABCA subfam-
ily that comprises 12 transporter proteins (Kaminski et al., 2006).
Luciani et al. (1994) identiﬁed both the Abca1 and Abca2 genes
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in several mouse tissues including the brain. The ABCA1 pro-
tein shares approximately 50% sequence homology with ABCA2
and although the transporters are localized in different cell com-
partments, both proteins are involved in lipid transport and
metabolism (Garewal et al., 1986; Davis et al., 2004; Mack et al.,
2007).
ABCA1
ABCA1, also known as cholesterol efﬂux regulatory protein, is a
plasma membrane protein that is highly expressed in the adrenal
gland and uterus. ABCA1 has also been detected in the CNS in
neurons, astrocytes,microglia, and in epithelial cells of the choroid
plexus (Figure 1; Koldamova et al., 2003;Kim et al., 2006; Fujiyoshi
et al., 2007). In porcine brain capillary endothelial cells, Abca1
protein has been localized to the basolateral plasma membrane
(Panzenboeck et al., 2002). In the periphery, ABCA1 mediates
cholesterol and phospholipid efﬂux from cells for transfer onto
lipid-free or lipid-poor apoprotein A-1 (ApoA-1) particles, the
main component of high density lipoproteins (HDL; Lawn et al.,
1999). Fully loaded, mature HDL particles then transport ApoA-
1-bound cholesterol and lipids from the tissues to the liver for
excretion or recycling. In 1999, researchers found that mutations
in the ABCA1 gene, resulting in a non-functional ABCA1 trans-
porter protein are the cause of Tangier disease, a rare autosomal
recessive disorder characterized by high cellular cholesterol and
low plasma HDL levels (Bodzioch et al., 1999). In individuals car-
rying two copies of themutantABCA1 gene, these changes in lipid
metabolism drastically increase the risk for cardiovascular disease.
In the CNS, ABCA1 mediates cholesterol and phospholipid
efﬂux from astrocytes andmicroglia thereby facilitating lipidation
of ApoE, which is the major apoprotein in the brain (Panzen-
boeck et al., 2002; Hirsch-Reinshagen et al., 2004). Consequently,
ABCA1-deﬁciency results in poorly lipidated ApoE particles, but
also in a thus far unexplained decrease in ApoE brain levels
(Hirsch-Reinshagen et al., 2004; Wahrle et al., 2004).
ABCA2
ABCA2 protein is predominantly expressed in the brain, where it
has been detected at the protein level in neurons,oligodendrocytes,
and brain capillary endothelial cells (Figure 1; Zhou et al., 2001;
Ohtsuki et al., 2004; Broccardo et al., 2006; Shawahna et al., 2011).
The primary location of ABCA2 is in the lysosomal membrane,
where it transports waste products from the cytoplasm into the
lysosomal compartment. In addition, studies suggest that ABCA2
plays a role in neural transmembrane lipid transport,macrophage
lipid metabolism, and neural development (Kaminski et al., 2001;
Zhou et al., 2001; Tachikawa et al., 2005; Broccardo et al., 2006).
However, in contrast to ABCA1, the function of ABCA2 is not
well-established.
ABCA1 AND ABCA2 IN AD
ABCA1
ABCA1-deﬁciency, ApoE, and Aβ brain levels. Changes in brain
cholesterol metabolism are linked to an increased risk of AD. One
important factor for brain cholesterol homeostasis is ApoE, which
supplies brain cells with cholesterol and lipids for development,
repair, and nerve growth. In 1993, Margaret Pericak-Vance and
her team conducted linkage and association analyses and discov-
ered that ApoE plays a critical role in AD (Corder et al., 1993). Of
the three major ApoE isoforms, ApoE-ε4 bears the highest genetic
risk factor for late-onset sporadic AD (Strittmatter et al., 1993),
and individuals carrying two ApoE-ε4 alleles have a 10–30 times
higher risk of developing AD compared to individuals not carry-
ing E-ε4 alleles (Farrer et al., 1997). In the AD ﬁeld, this increased
risk is thought to be due to ApoE-ε4 directly interacting with Aβ,
thereby favoringAβ aggregation and plaque formation (Holtzman
et al., 2000). Since ABCA1 promotes cholesterol and phospholipid
efﬂux to ApoE particles and inﬂuences lipidation of apolipopro-
teins and ApoE brain levels, researchers postulated a potential role
for ABCA1 in AD pathology.
In this regard, Hirsch-Reinshagen et al. (2004) found that
Abca1-deﬁciency inmice leads to reduced lipid efﬂux toApoE and,
for an unknown reason, also in a dramatic decrease of ApoE brain
levels. The same group also showed in two hAPP-overexpressing
AD mouse models (Tg-SwDI/B; APP/PS1) that Abca1-deﬁciency
reduces ApoE brain levels, but has no effect on Aβ brain levels
(Hirsch-Reinshagen et al., 2005). In contrast, two other studies
demonstrate that a lack of Abca1 in hAPP-overexpressing mice
(APP23 and PDAPP models) decreases both ApoE lipidation and
ApoE brain levels, and also increases brain levels of insoluble Aβ40
and Aβ42 (Koldamova et al., 2005a; Wahrle et al., 2005). From
these observations, the authors concluded that poorly lipidated
ApoE has a high afﬁnity to Aβ and promotes Aβ ﬁbrillogenesis.
ABCA1 upregulation, ApoE, and Aβ brain levels. Several groups
studied the impact of inducing Abca1 protein in mouse on ApoE
and Aβ brain levels. ABCA1 gene transcription is controlled by
the ligand-activated nuclear receptors LXRα and β (liver X recep-
tor), which are key regulators of cholesterol and lipid metabolism
(Whitney et al., 2002). Fukumoto et al. (2002) conducted the ﬁrst
in vitro study on the effect of LXR activation on Abca1 protein
expression. Using mouse Neuro2A cells, the authors showed that
upregulation of Abca1 protein levels by various LXR activators
increased secretion of bothAβ40 andAβ42. This effect was reduced
when Abca1 expression was blocked with RNAi (Fukumoto et al.,
2002). However, these ﬁndings could not be reproduced in sub-
sequent in vitro studies. In a variety of mouse and human cell
lines transfected with Swedish or wild-type APP, LXR-mediated
Abca1 and ABCA1 induction reduced Aβ production and secre-
tion (Koldamova et al., 2003; Sun et al., 2003; Brown et al., 2004;
Kim et al., 2007, 2009). This observation is consistent with ﬁnd-
ings from in vivo studies using LXR agonists in ADmousemodels.
Koldamova et al. (2005b) showed that treatment of 11-week-old
APP23 mice with T0901317, a synthetic LXR ligand, increased
Abca1 protein expression and signiﬁcantly decreased brain levels
of Aβ40 and Aβ42. Similar results were also published by other
groups (Burns et al., 2006; Lefterov et al., 2007; Riddell et al.,
2007; Jiang et al., 2008). Even in 40-week-oldAPP/PS1mice, LXR-
mediated upregulation of Abca1 andApoEprotein levels improved
cognitive impairment in the novel object recognition test, while
cognition remained unchanged inAPP/PS1-Abca1-deﬁcientmice.
Although a reduction in Aβ burden was observed, guanidine-
soluble or mature Aβ levels were not signiﬁcantly reduced in mice
with increased Abca1 expression compared to Abca1-deﬁcient
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FIGURE 1 | Map of the ABC transporters ABCA1,ABCA2, P-gp, MRP1, and BCRP in the CNS. Modiﬁed according to Hartz and Bauer (2011).
mice (Donkin et al., 2010). These observations are consistent with
ﬁndings by Vanmierlo et al. (2009) who also demonstrated that
LXR activation improvedmemory function in agedAPP/PS1mice
without reducing Aβ deposition.
Zelcer et al. used a different approach andquantiﬁedAβplaques
in the brains of APP/PS1mice lacking either LXRα or LXRβ. LXR-
deﬁciency resulted in reduced Abca1 and ApoE protein levels, and
increasedAβ brain levels compared towild-typemice (Zelcer et al.,
2007).
To further clarify the role of Abca1 in AD,Wahrle et al. (2008)
generated Abca1-overexpressing PDAPP mice. In these mice, Aβ
load was signiﬁcantly decreased at 12months of age, and with
sixfold Abca1 protein overexpression, Aβ deposition was almost
absent. Furthermore, hippocampal ApoE levels were signiﬁcantly
decreased in Abca1-overexpressing PDAPP mice, the proportion
of insoluble ApoE was increased, and ApoE showed increased
lipidation (Wahrle et al., 2008).
Although Abca1 upregulation has been shown to decrease Aβ
brain burden in AD mouse models and exert a beneﬁcial effect,
its role in AD is not fully understood. ABCA1 does not directly
transport Aβ (Akanuma et al., 2008), rather it acts as a cholesterol
and phospholipid transporter. Thus, ABCA1 affects ApoE lipi-
dation and brain cholesterol homeostasis, factors that have been
shown to inﬂuence APP processing and Aβ aggregation (Simons
et al., 1998; Puglielli et al., 2003). Abca1-deﬁciency in mice results
in poorly lipidated ApoE and in reduced brain levels of soluble
ApoE (Koldamova et al., 2005a; Wahrle et al., 2005). Interestingly,
lowApoEbrain levels per se are associatedwith decreasedAβdepo-
sition, while poorly lipidated ApoE has been discussed to have an
amyloidogenic effect in vivo (Koldamova et al., 2005a;Wahrle et al.,
2005). The underlying mechanism(s) of these observations is/are
largely unknown and more studies are required to unravel the
complex interrelation between ABCA1, brain lipid metabolism,
and AD.
ABCA1 expression in AD. Recent studies also analyzed ABCA1
expression in post-mortem brain tissue samples fromADpatients.
Akram et al. found increased ABCA1 mRNA and protein expres-
sion in hippocampal brain tissue from AD patients compared
to age-matched control subjects. ABCA1 mRNA expression
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correlated with the severity of dementia, Braak score (tau tan-
gles), and Aβ plaque density, whereas ABCA1 protein expres-
sion correlated with dementia severity and Braak score, but not
with plaque density (Akram et al., 2010). Kim et al. (2010)
also found increased ABCA1 protein and mRNA levels in hip-
pocampal tissue from AD patients compared to age-matched
controls.
ABCA1 polymorphisms and AD. A total of 14 studies have been
conducted to investigate the association of ABCA1 gene polymor-
phisms with the risk for AD (Wollmer et al., 2003; Katzov et al.,
2004; Li et al., 2004; Kolsch et al., 2006; Shibata et al., 2006; Chu
et al., 2007; Rodriguez-Rodriguez et al., 2007, 2009, 2010; Sundar
et al., 2007; Wahrle et al., 2007; Wang and Jia, 2007; Wavrant-De
Vrieze et al., 2007; Reynolds et al., 2009). Eight of these studies
link single nucleotide polymorphisms (SNP) in the ABCA1 gene
to an increased risk for AD (Katzov et al., 2004; Shibata et al.,
2006; Chu et al., 2007; Rodriguez-Rodriguez et al., 2007; Sun-
dar et al., 2007; Wang and Jia, 2007; Wavrant-De Vrieze et al.,
2007; Reynolds et al., 2009). In summary, the SNP rs2230808 was
associated with increased tau and Aβ brain levels, the C-alleles
of the G-395C polymorphisms were associated with decreased
cerebrospinal ﬂuid (CSF) levels of 24-hydroxycholesterol, and
the rs2230805 allele was associated with reduced Aβ42 CSF lev-
els (Wollmer et al., 2003; Katzov et al., 2004; Kolsch et al., 2006;
Reynolds et al., 2009). In addition, individuals carrying poly-
morphisms of the ABCA1 and the Niemann-Pick C1 genes, and
individuals with polymorphisms of ABCA1 in conjunction with
polymorphisms of hydroxy-methylglutaryl-coenzyme A reduc-
tase, have an increased risk for AD (Rodriguez-Rodriguez et al.,
2009, 2010).
ABCA2
In contrast to ABCA1, little is known about ABCA2 in AD.
Recently, researchers identiﬁed a synonymous SNP (rs908832) in
exon 14 that is associated with a high risk for sporadic, early-
onset AD, but not late-onset AD (Mace et al., 2005). These results
were conﬁrmed by Wollmer et al.; however, their data indicate
that the genetic association of ABCA2 with sporadic AD depends
on ethnicity. While these authors found a strong association of
rs908832 with AD in a Western European population, no such
association was found for Southern Europeans (Wollmer et al.,
2006).
In addition, a number of independent results from different
studies point to a possible role of ABCA2 in AD pathology: (1)
ABCA2 protein has been found to co-localize with both APP
and Aβ in vitro (Chen et al., 2004); (2) ABCA2 overexpression
increases APP and Aβ-levels and upregulates a number of genes
associated with resistance to oxidative stress (Chen et al., 2004);
(3) β-secretase-1, which is involved in the generation of Aβ40 and
Aβ42, is decreased in an Abca2-overexpressing mouse neuroblas-
toma N2a cell line (Davis, 2010); (4), ABCA2 protein expression is
increased in temporal lobe samples fromAD patients (Chen et al.,
2004); and most recently (5) ABCA2 downregulation with siRNA
reduces Aβ production in vitro, which is an interesting ﬁnding
given that this is the opposite of what has been found for ABCA1
(Michaki et al., 2012).
ABCA1 AND ABCA2 AS POTENTIAL THERAPEUTIC TARGET IN AD
AlthoughABCA1andABCA2aremembers of the sameABC trans-
porter subfamily, they are different with regard to their physiolog-
ical functions and potential involvement in AD pathophysiology.
In the CNS, ABCA1 is important for proper lipidation of apopro-
teins. Reduced ABCA1 protein levels result in lipid-poor ApoE,
which seems to increase Aβ aggregation. Several studies demon-
strated that LXR-mediated Abca1 upregulation increases ApoE
levels, decreases Aβ brain levels, and has beneﬁcial effects on cog-
nition in ADmouse models (Koldamova et al., 2005b; Burns et al.,
2006; Lefterov et al., 2007; Riddell et al., 2007; Jiang et al., 2008;
Donkin et al., 2010). Since numerous compounds are available
to activate LXR, this approach might be a potential therapeutic
strategy for AD. However, in addition to ABCA1 upregulation,
activating LXR also increases expression levels of ABCG1, another
lipid transporter of the ABC superfamily, and ApoE. This is of
relevance, since both ABCG1 andApoE have been implicated with
AD as well (Corder et al., 1993; Wollmer et al., 2007). Conse-
quently, the beneﬁcial effects of LXR activation could be a result
of upregulating one, two, or all of these proteins, and possibly
include other proteins that control lipid transport and metabo-
lism, such as Cyp7A1 or cholesterol ester transfer protein (Repa
et al., 2000; Tall et al., 2000; Honzumi et al., 2010). Thus, due to
the complexity of the LXR regulatory network, interpretation of
study results is difﬁcult and more research is needed to discern
the roles of ABCA1, ABCG1, ApoE, and possibly other proteins in
AD.
In contrast to ABCA1, overexpression of ABCA2 increases APP
synthesis, altersAPPprocessing, and elevatesAβ brain levels (Chen
et al., 2004; Davis, 2010). This suggests that ABCA2 downregula-
tion could potentially reduce Aβ brain levels and have a beneﬁcial
effect on cognition. To date, no studies exist that clarify ABCA2
function under physiological and pathophysiological conditions
and properly test the hypothesis that ABCA2 downregulation
could be a potential therapeutic strategy in AD.
P-GLYCOPROTEIN
BACKGROUND
Juliano and Ling (1976) discovered a 170 kDa transmembrane
protein in a Chinese hamster ovary cell line and named it P-
glycoprotein (P-gp). Shortly thereafter, in 1983, P-gp was found
in a human tumor cell line (Kartner et al., 1983), and in 1988 it
was detected in normal liver tissue and small intestine mucosa
(Hitchins et al., 1988). Since then, P-gp has become the most
prominent transporter of the ABC family. In humans, P-gp is
encoded by theABCB1 gene (MDR1), and in rodents by theAbc1a
(Mdr1a) and Abc1b (Mdr1b) genes (Ueda et al., 1986; Hsu et al.,
1989).
A number of barrier and excretory tissues throughout the
human body express P-gp, including intestine, liver, kidney, and
the blood-placenta and blood-testis barriers. In the CNS, P-gp
has relatively low expression levels in neurons, astrocytes, per-
icytes, microglia, and the epithelial cells of the choroid plexus
(Figure 1; Lee and Bendayan, 2004). In contrast, the highest P-
gp expression levels in the body are found in the brain capillary
endothelium comprising the blood-brain barrier (Thiebaut et al.,
1987; Cordon-Cardo et al., 1989).
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P-gp is a potent and efﬁcient efﬂux transporter that prevents a
variety of structurally diverse compounds, primarily amphiphilic
and slightly cationic organic chemicals, including therapeutic
drugs and toxicants, from entering the brain and pumpsmetabolic
waste products out of the brain. Thus, P-gp plays a crucial role
in neuroprotection, brain detoxiﬁcation, and overall CNS home-
ostasis (Schinkel, 1999; Schinkel and Jonker, 2003). Therefore,
deletion or inhibition of P-gp can result in signiﬁcantly increased
brain uptake of its substrates. For example,Mdr1a knockout mice
showed a 10- to 50-fold increase in brain concentrations of vin-
blastine and ivermectin, respectively (Schinkel et al., 1994). Like-
wise, direct inhibition of P-gp with valspodar (PSC833) increased
brain levels of methadone, digoxin, paclitaxel, and colchicine by 5-
to 10-fold (Desrayaud et al., 1997; Mayer et al., 1997; Fellner et al.,
2002; Rodriguez et al., 2004).
Although it is well-established that P-gp can handle a large
number of exogenous compounds (Schinkel, 1999), it is still
unknown if P-gp has endogenous substrates. Recent reports show
that P-gp effectively transports Aβ at the blood-brain barrier, indi-
cating that amyloid peptides may be endogenous P-gp substrates
(Cirrito et al., 2005; Hartz et al., 2010). Importantly, these ﬁnd-
ings link blood-brain barrier P-gp to AD and are described in the
following section.
P-GLYCOPROTEIN IN AD
Lam et al. (2001) were the ﬁrst to suggest that P-gp is capable of
transportingAβ. In their study, the authors co-transfectedHEK293
cells with human MDR1 and the gene coding for the human amy-
loid precursor protein hAPP, and observed increased Aβ secretion
from APP/MDR1-co-transfected cells compared to cells that were
only transfected with hAPP, but not with MDR1. Moreover, treat-
ment with P-gp inhibitors signiﬁcantly decreased Aβ secretion in
MDR1-transfected cells. However, since cellular APP levels were
increased inMDR1-transfected cells, it was unclear if increasedAβ
secretion was due to P-gp-mediated transport or a result of higher
intracellular Aβ levels. In additional experiments using inside-
outmembrane vesicles isolated fromP-gp overexpressingCHRB30
cells, Lam et al. also showed that Aβ40 and Aβ42 transport is ATP-
dependent. From this study Lam et al. (2001) concluded that P-gp
facilitatesAβ transport and proposed thatABC transporters could,
in general, act as Aβ efﬂux pumps.
Consistent with these ﬁndings, Kuhnke et al. (2007) demon-
strated increased basal-to-apical transport of FITC-labeled Aβ40
and Aβ42 in MDR1-transfected LLC-PK1 cells compared to LLC-
PK1 parental cells; this effect was blocked by the P-gp inhibitor
cyclosporine A. The authors then reversed the experiment and
showed that Aβ40 and Aβ42 inhibit transport of the ﬂuores-
cent P-gp substrate rhodamine 123, suggesting Aβ transport is
competitive. Lastly, using inside-out membrane vesicles from
MDR1-transfected and parental LLC-PK1 cells, Kuhnke et al.
(2007) demonstrated that transport of both rhodamine 123 and
FITC-labeled Aβ in vesicles from MDR1-transfected LLC cells is
ATP-dependent. Thus, Kuhnke et al. provided further evidence
indicating that P-gp transports Aβ.
In a comprehensive in vivo study, Cirrito et al. (2005) provided
ﬁrst evidence for a direct link between blood-brain barrier P-
gp and Aβ brain deposition. Using Mdrla/b−/− double-knockout
mice, the authors ﬁrst showed that brain clearance of Aβ40 and
Aβ42 was signiﬁcantly lower compared to that in control animals
30min after intracerebral microinjection of the amyloid peptides.
Then, the authors dosed transgenic hAPP-overexpressing mice,
a well-established AD model (Tg2576 mice; Hsiao et al., 1996),
with the selective P-gp inhibitor XR9576 (tariquidar) and mea-
sured Aβ brain concentrations by microdialysis. As early as 8 h
after injecting hAPP mice with the P-gp inhibitor, Aβ levels in
the brain interstitial ﬂuid were signiﬁcantly increased compared
to untreated hAPP control mice (Cirrito et al., 2005). Consistent
with this, 12-month-old P-gp-deﬁcient hAPP mice had a higher
Aβ brain load compared to hAPP mice expressing P-gp. Thus,
Cirrito et al. (2005) demonstrated for the ﬁrst time that reduced
blood-brain barrier P-gp activity due to an inhibitor or a genetic
lack of P-gp increases Aβ brain uptake and reduces Aβ brain clear-
ance in anADmousemodel, which further substantiates that P-gp
could be a contributing factor in AD pathology.
Several groups studied P-gp expression at the human blood-
brain barrier and correlated the results with Aβ load in the sur-
rounding brain tissue. Vogelgesang et al. (2002) analyzed vascular
P-gp protein expression and cerebral Aβ load in post-mortem
brain tissue samples from non-demented elderly patients and
found that P-gp levels were low in the vasculature surrounding
Aβ plaques. In another study, the same authors analyzed post-
mortem brain tissue samples from non-demented elderly patients
with cerebral amyloid angiopathy (CAA), a disease caused by Aβ
deposition in the cerebrovasculature. In these samples, brain cap-
illaries with Aβ deposition showed no P-gp immunoreactivity,
whereas P-gp immunostaining was increased in capillaries with no
Aβ deposition compared to control samples (Vogelgesang et al.,
2004). In a recent study Wijesuriya et al. (2010) detected 25%
lower P-gp protein expression levels in hippocampal blood vessels
in post-mortem brain samples from AD patients than in sam-
ples fromage-matchednon-demented patients. Jeynes andProvias
(2011) made similar observations in post-mortem cerebral cortex
tissue samples from 10 AD patients: in areas with a high density of
Aβ40 plaques and neuroﬁbrillary tangles, respectively, P-gp protein
expression levels were decreased compared to levels found in tis-
sue samples from non-demented individuals. Thus, these studies
indicate an inverse correlation between Aβ deposition and vascu-
lar P-gp expression at the human blood-brain barrier in AD, that
is: high Aβ brain levels correlate with low vascular P-gp levels and
vice versa.
In a recent study, van Assema et al. (2012) used positron emis-
sion tomography and the P-gp substrate (R)-[11C]verapamil to
assess blood-brain barrier P-gp function in AD patients with
that of age-matched healthy control subjects. The authors found
an increase in the non-displaceable binding potential of (R)-
[11C]verapamil in several cortical brain regions of AD patients
compared to healthy control individuals. These are critical data
since they provide ﬁrst direct evidence for reduced P-gp function
at the blood-brain barrier of AD patients.
Zlokovic and Frangione (2003) proposed the “transport-
clearance hypothesis” of AD. This hypothesis states that increased
Aβ brain accumulation in AD is due to reduced Aβ clear-
ance from brain to blood. Based on Zlokovic’s Aβ transport-
clearance hypothesis and the above-mentioned previous ﬁndings,
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we postulated that Aβ clearance from brain to blood occurs in two
steps, and that each step must be facilitated by a transporter or
receptor since Aβ is a peptide that does not easily cross the plasma
membrane by itself. In the ﬁrst step, Aβ must pass from the brain
parenchyma through the abluminal plasmamembrane of the cap-
illary endothelium into brain capillary endothelial cells. Studies
suggest that the low-density lipoprotein receptor-related protein 1
(LRP1) facilitates this step (Shibata et al., 2000; Deane et al., 2004;
Fujiyoshi et al., 2011). In the second step,Aβmust pass from brain
capillary endothelial cells across the luminal plasma membrane
into the blood of the neurovasculature. We hypothesized that (1)
P-glycoproteinmediates this critical, because rate-limiting, second
step of the neurovascular Aβ clearance process, that (2) it is this P-
gp-mediated step in the neurovascular Aβ clearance process that is
impaired in AD, and consequently, that (3) restoring blood-brain
barrier P-gp lowers Aβ brain levels in AD.
We addressed these hypotheses in a recent study (Hartz
et al., 2010). First, we demonstrated P-gp-mediated transport of
ﬂuorescein-labeled Aβ42 in intact, living isolated mouse brain
capillaries ex vivo. This was the ﬁrst direct evidence that P-
gp mediates Aβ transport at the blood-brain barrier. In con-
trast, our data showed that Bcrp and Mrp2 are not involved in
Aβ42 transport in isolated brain capillaries from mouse (Hartz
et al., 2010). Second, using the transgenic hAPP-overexpressing
mouse model (Tg2576 mice) we showed that P-gp is compro-
mised at the blood-brain barrier. We found a 70% decrease
in P-gp transport activity and a 60% decrease in P-gp protein
expression in isolated brain capillaries from hAPP mice com-
pared to age-matchedwild-typemice. These ﬁndings demonstrate
that, similar to ﬁndings in humans, P-gp expression and func-
tion are signiﬁcantly reduced at the blood-brain barrier in mice
with high Aβ brain levels. Next, we showed that dosing hAPP
mice with pregnenolone-16α-carbonitrile (PCN) once daily for
7 days to activate the pregnane X receptor (PXR) completely
restored P-gp expression and transport activity in brain cap-
illaries. As a consequence, Aβ40 and Aβ42 levels were reduced
in capillaries from hAPP mice by approximately 30%. Further-
more, PCN-treatment lowered Aβ40 and Aβ42 brain levels by
approximately 50–65% compared to untreated hAPP mice. Thus,
our study conﬁrms that blood-brain barrier P-gp plays a role
in the Aβ brain clearance process, which suggests that restor-
ing blood-brain barrier P-gp could potentially be used as a new
therapeutic strategy to lower Aβ brain levels in AD (Hartz et al.,
2010).
In addition to countless physiological and pharmacological
studies on P-gp, the number of pharmacogenomic studies on its
gene ABCB1 is increasing. Yet, the only published pharmacoge-
nomic association study on ABCB1 and AD is by Kohen et al.
(2011). These authors hypothesized the existence of a link between
commonABCB1 SNPs such as G2677T/A and C3435T and the age
of AD onset and/or Aβ42 CSF levels in AD patients. However, no
signiﬁcant association was found and it remains to be elucidated if
ABCB1 polymorphisms that may alter transport function and/or
expression play a role in AD.
In summary, research over the last 10 years indicates that P-gp
at the blood-brain barrier is part of the process involved in clearing
Aβ from brain to blood. These ﬁndings put P-gp in the spotlight
as potential therapeutic target in AD, which will be discussed in
the next section.
P-GLYCOPROTEIN AS POTENTIAL THERAPEUTIC TARGET IN AD
Given its critical role in the neurovascular Aβ clearance system,
P-gp could potentially be used as a therapeutic target in AD.
As mentioned above, activation of the nuclear receptor PXR to
restore blood-brain barrier P-gp, and thus, to reduce Aβ brain
burden and slow cognitive decline has been proposed as a novel
strategy (Hartz et al., 2010). In this regard, Loeb et al. (2004)
showed in a randomized, triple-blind and controlled clinical trial
that treating patients with mild to moderate AD with the antibi-
otics doxycycline and rifampicin daily for 3months signiﬁcantly
slowed cognitive decline compared to patients in the control
group. This effect lasted for up to 9months beyond the treat-
ment period, and the authors stated that the mechanism for this
positive clinical beneﬁt was unknown, but unlikely to be due to
the antibiotic effect. Interestingly, both doxycycline and rifampicin
activate PXR (Mealey et al., 2002; Yasuda et al., 2008). Thus, one
possible explanation for slowed cognitive decline in these patients
is that doxycycline and rifampicin activated PXR, which increased
blood-brain barrier P-gp levels, and in turn could have increased
Aβ brain clearance, loweredAβ brain levels, and thus, reduced pro-
gressive decline of cognition. This hypothesis, however, remains to
be veriﬁed.
Another strategy is to unravel the underlyingmechanism/s that
reduce/s blood-brain barrier P-gp expression levels and functional
activity in AD. Knowledge of this/these mechanism/s could help
identify targets to protect P-gp, maintain Aβ brain clearance, pre-
vent or slow Aβ brain accumulation, and thereby prevent or delay
AD. In a recent study, Brenn et al. investigated the effect of Aβ
on blood-brain barrier P-gp and LRP expression in mice. Aβ40
and Aβ42 were administered through a subcutaneously implanted
ALZET Mini-Osmotic pump for 24 h. The authors showed that
only Aβ42 signiﬁcantly decreased both Abcb1 and LRP1 mRNA
expression levels in vivo, but no changes were observed at the pro-
tein level (Brenn et al., 2011). However, this could have been due
to peripheral Aβ administration, rather than administering Aβ to
the brain,whichwould havemimickedADpathologymore closely.
Other studies addressing themechanism/s that reduce blood-brain
barrier P-gp in AD are not available.
Clearly, studies indicate that restoring P-gp expression and
function could be effective in enhancing Aβ clearance from the
brain and lower Aβ brain levels (Cirrito et al., 2005; Hartz et al.,
2010). However, the concept that restoring P-gp at the blood-brain
barrier could serve as a valid therapeutic strategy to lowerAβ brain
load, reduce cognitive decline, delay onset and slow progression of
AD now has to be critically evaluated.
MRP1
BACKGROUND
MRP1 was discovered by Cole et al. (1992) in the H69AR can-
cer cell line. Unlike P-gp, which mainly handles amphiphilic and
slightly cationic chemicals, MRP1 substrates are mainly organic
anions. TheMRP1 substrate spectrum includes endogenous com-
pounds like leukotriene C4, glutathione, glucuronide, and sulfate
conjugates, as well as a variety of exogenous compounds such as
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chemotherapeutics, HIV protease inhibitors, antibiotics, and tox-
ins (Loe et al., 1996;Conseil et al., 2005). In the humanbody,MRP1
is expressed in most tissues, including kidney, lung, placenta, and
liver. In the brain, MRP1 protein expression has been detected
in astrocytes, microglia, pericytes, neurons, the basolateral mem-
brane of choroid plexus cells, and the luminal and abluminal
membranes of brain capillary endothelial cells (Figure 1; Schinkel,
2001; Soontornmalai et al., 2006; Roberts et al., 2008). Based on
this expression pattern and substrate spectrum, the main func-
tion of MRP1 is extrusion of glutathione, glucuronide, and sulfate
metabolites, as well as cell protection against potentially harm-
ful metabolites, xenobiotics, and drugs. Since increasing evidence
indicates involvement of ABC transporters in neurodegenerative
diseases, researchers were prompted to investigate MRP1 in AD.
MRP1 IN AD
Currently, two studies implicateMRP1 (ABCC1)withAD.Theﬁrst
study is concerned with the effect of 4-hydroxy-2-trans-non-enal
(HNE) on the metabolizing enzyme glutathione-S-transferase-α
(GST-α) andMRP1 inAD (Sultana and Butterﬁeld, 2004). HNE is
a neurotoxic product of membrane lipid peroxidation (Mark et al.,
1997). Under physiological conditions, HNE is ﬁrst inactivated by
GST-α through conjugation with glutathione, and then, in a sec-
ond step, the HNE-glutathione conjugate is transported out of the
cell by MRP1 to limit toxicity (Loe et al., 1996).
In AD, however, due to increased oxidative stress, high levels of
HNE are present in the brain (Lovell et al., 1997). In this regard,
Sultana and Butterﬁeld showed that HNE co-immunoprecipitates
with both GST-α and MRP1 to a greater extent in post-mortem
hippocampal tissue samples from AD patients compared to sam-
ples from aged-matched control individuals. The authors con-
cluded that excess HNE in AD brain leads to covalent binding of
HNE to GST-α and MRP1, and speculated that this could impair
GST-α and MRP1 function, resulting in cellular accumulation of
GST-α and MRP1 substrates, which could promote neurotoxicity.
However, more studies are required to verify this conclusion and
to demonstrate the proposed sequence of events.
The second study that implicates Mrp1 with AD was recently
published by Krohn et al. (2011). The authors used double trans-
genic mice expressing both human APP and human presenilin-
1 (APP/PS1), and, in addition, generated APP/PS1 mice lack-
ing Abcb1 (P-gp), Abcg2 (Bcrp), or Abcc1 (Mrp1), respectively.
Krohn et al. showed an age-dependent increase of Aβ40 and
Aβ42 (guanidine-soluble fraction) and increased coverage and
size of Aβ plaques in the cortex of APP/PS1×Abcc1−/− mice
(Mrp1-deﬁcient) compared to control APP/PS1 mice. The num-
ber and size of Aβ plaques and Aβ levels in the brains of
APP/PS1×Abcb1−/− mice (P-gp-deﬁcient) were also elevated
compared to control animals; no difference was observed between
APP/PS1×Abcg2−/− mice (Bcrp-deﬁcient) and control animals.
Using a Transwell assay with primary cultured endothelial cell
monolayers from standard Abcc1−/− and wild-type mice, Krohn
et al. also showed that abluminal-to-luminal Aβ42 transport was
signiﬁcantly reduced in Mrp1-deﬁcient cells.
In additional experiments, the authors tested if activation
of Mrp1 reduces Aβ brain levels by dosing APP/PS1 and
APP/PS1×Abcc1−/− mice with thiethylperazine twice daily for
30 days. Thiethylperazine is a phenothiazine derivative that
has been shown to increase Mrp1 activity in mature human
red blood cells (Wesolowska et al., 2009). ELISA measure-
ments showed that soluble Aβ42 brain levels were signiﬁcantly
reduced in thiethylperazine-treated APP/PS1 but not in untreated
APP/PS1×Abcc1−/− mice. Furthermore, both number and size of
Aβ plaques were reduced, and brain levels of both aggregated and
soluble Aβ42 were lowered, although the decrease in aggregated
Aβ42 was not signiﬁcant. A reduction in Aβ brain levels was also
observed in APP/PS1×Abcb1−/− mice, suggesting that activation
of Mrp1 was the reason for reduced Aβ brain levels (Krohn et al.,
2011).
MRP1 AS POTENTIAL THERAPEUTIC TARGET IN AD
Currently, the report by Krohn et al. (2011) is the ﬁrst and only
evidence that suggests a potentially important role for Mrp1 in
Aβ removal from the mouse brain in vivo. More importantly,
the authors provide proof-of-principle of a potential new ther-
apeutic strategy to treat AD. Three critical points remain to be
addressed. First, the detailed molecular mechanism by which thi-
ethylperazine affects Mrp1, and possibly other transporters in
mouse (and eventually in humans), needs to be elucidated. Such
knowledge is critical given that thiethylperazine seems to activate
Mrp1 while inhibiting P-gp at same time. In addition, although
thiethylperazine dosing decreased Aβ brain load, the direct effect
on blood-brain barrierMrp1 expression and/or functional activity
in vivo remains unknown. Second,MRP1 localization at the blood-
brain barrier in humans and rodents is controversial. While some
studies show MRP1 to be localized in the luminal plasma mem-
brane, other studies detected MRP1 expression in the abluminal
plasmamembrane (Nies et al., 2004; Zhang et al., 2004; Soontorn-
malai et al., 2006; Kilic et al., 2008). However, a recent study by
Roberts et al. (2008) indicates that ratMrp1 is expressed at both the
luminal and abluminalmembranes of the brain capillary endothe-
lium. Based on this ﬁnding, MRP1-mediated Aβ transport could
occur in two directions: (1) into the brain by abluminalMRP1, and
(2) out of the brain into the capillary lumen by luminal MRP1.
Third and last, direct evidence is available that P-gp transports Aβ
at the blood-brain barrier, but such direct proof is not yet available
for MRP1. Together, more studies are required to conﬁrm existing
data and unequivocally demonstrate that MRP1 is involved in Aβ
brain clearance and a valid target for AD treatment.
BCRP
BACKGROUND
ABCG2 is the gene that codes for the breast cancer resistance pro-
tein (BCRP), which was ﬁrst discovered in 1998 in the human
breast cancer cell line MCF-7/AdrVp (Allikmets and Dean, 1998;
Doyle et al., 1998). BCRP is a half-transporter that functions as
a homodimer or oligomer, and despite its name, is expressed
throughout the human body (Nakanishi et al., 2003; Xu et al.,
2004). BCRP has been found in placenta, testis, GI tract, kid-
ney, liver canalicular membrane, and in hematopoietic stem cells
(Maliepaard et al., 2001; Scharenberg et al., 2002; Bart et al., 2004;
Huls et al., 2008). In the CNS, BCRP expression has been detected
in pericytes, microglia, astrocytes, in neural progenitor, and stem
cells (Figure 1; Islam et al., 2005; Mouthon et al., 2006; Lee et al.,
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2007; Shimizu et al., 2008), and it is highly expressed in the luminal
membrane of brain capillary endothelial cells (Cooray et al., 2002;
Eisenblatter and Galla, 2002; Zhang et al., 2003; Dauchy et al.,
2008). BCRP tissue distribution and substrate spectrum greatly
overlap with those of P-gp, and recent evidence indicates that at
the blood-brain barrier, BCRP and P-gp work together in a “coor-
dinated” fashion to transport chemotherapeutic drugs (Schinkel
and Jonker, 2003; de Vries et al., 2007; Chen et al., 2009). In this
regard, researchers currently study the involvement of BCRP in
Aβ transport across the blood-brain barrier and its possible role
in AD.
BCRP IN AD
The recently described concept that BCRP and P-gp “team up and
work together” in transporting chemotherapeutics at the blood-
brain barrier may possibly be extended to their handling of Aβ.
In a review article, Pahnke et al. (2008) stated that BCRP par-
tially compensates for a loss in P-gp-mediated Aβ clearance in
hAPP-overexpressing ADmouse models that are P-gp-deﬁcient at
the blood-brain barrier. However, these data appear to be unpub-
lished, and thus, the details of this work are unclear. In contrast,
the same group showed that there was no difference in Aβ load
and plaque size inAPP/PS1×Abcg2−/− mice compared to control
APP/PS1 mice, indicating that Bcrp is not involved in the process
that clears Aβ from the brain (Krohn et al., 2011). Consistent with
this, we showed that Bcrp is not involved in Aβ42 transport in iso-
lated brain capillaries of wild-type and hAPP mice (Hartz et al.,
2010).
In another study, Xiong et al. analyzed cerebral cortex sam-
ples from AD patients and patients with AD/CAA with qPCR,
Western blotting, and immunohistochemistry. Expression of both
BCRP mRNA and protein were signiﬁcantly increased in sam-
ples from AD/CAA patients compared to control samples from
age-matched non-demented individuals. This same trend was
observed in brain tissue samples from AD patients (Xiong et al.,
2009). In contrast, Wijesuriya et al. (2010) found no changes in
BCRP protein expression in hippocampal blood vessels of sam-
ples from AD patients when compared to control samples from
age-matched non-demented individuals. In further experiments,
Xiong et al. used triple-transgenic 3XTg mice that overexpress
human APP, presenilin-1, and tau, and that constitute the only
AD model that exhibits both Aβ and tau pathology. The authors
showed that capillary Bcrp protein expression was increased in
brain sections from 10-month-old 3XTg mice that had high Aβ
brain deposits in the parenchyma and spatially close to brain cap-
illaries compared to wild-type mice. To test if Aβ affects BCRP
transport function,Xiong et al. then exposed hABCG2-transfected
HEK293 cells to Aβ40. Accumulation of the ﬂuorescent BCRP
substrate Hoechst 33342 was signiﬁcantly higher in cells treated
with Aβ40 compared to untreated and empty-vector transfected
cells, suggesting that Aβ interacts with BCRP, thereby impair-
ing BCRP-mediated efﬂux transport. The authors also dosed
Abcg2 knockout mice intravenously with Cy5.5-labeled Aβ40 and,
using in vivo imaging, found signiﬁcantly higher Cy5.5 ﬂuores-
cence in the brains of Bcrp knockout mice compared to brains
from wild-type mice. This effect was not observed after inject-
ing Cy5.5-labeled scrambled Aβ40 (Xiong et al., 2009). From
these data the authors concluded that BCRP may act as a gate-
keeper at the blood-brain barrier to prevent Aβ from entering the
brain.
In another study, Tai et al. (2009) used the human brain
endothelial cell line hCMEC/D3 and showed that P-gp and BCRP
inhibitors reducedAβ40 efﬂux fromcells preloadedwith 125I-Aβ40.
Inhibition of P-gp or BCRP increased apical-to-basolateral, but
not basolateral-to-apical permeation of 125I-Aβ40. The authors
concluded that both P-gp and BCRP transport Aβ40 and that P-gp
and BCRP prevent apical-to-basolateral transport, but may not be
involved in basolateral-to-apical Aβ transport.
A potential protective role of BCRP against oxidative stress
in AD was proposed by Shen et al. (2010). Using ABCG2-
overexpressing HEK293 cells, the authors demonstrated that
BCRP inhibits NFκB activation, which reduces oxidative stress.
Consistent with this, Shen et al. found increased levels of phos-
phorylated IκB-α,which leads toNFκB activation, andhigherAβ40
levels in brain tissue from Abcg2−/− mice compared to wild-type
mice. Based on these ﬁndings, the authors proposed that upregu-
lation of blood-brain barrier BCRP in AD is an adaptive response
to reduce oxidative stress through inhibition of theNFκB signaling
pathway.
Finally, only one pharmacogenomic study is available where an
association between BCRP polymorphisms and AD was investi-
gated. In this genome-wide association study that involved screen-
ing the potential CSF biomarkers Aβ42, total tau, and p-tau181
across the genomes of patient samples, Kim et al. (2011) identi-
ﬁed one SNP (rs11724427) in the ABCG2 gene that is possibly
associated with a higher risk for AD. However, it remains to be
seen if ABCG2 polymorphisms play a role in AD etiology and
pathology.
BCRP AS POTENTIAL THERAPEUTIC TARGET IN AD
Soon after the ﬁrst studies on P-gp and AD were published,
researchers hypothesized that BCRP also transports Aβ and con-
tributes to Aβ brain clearance. However, the data that are available
are conﬂicting and, at this point, the picture of BCRP in AD is
inconsistent and incomplete.While some studies show that BCRP
transports Aβ (Tai et al., 2009; Xiong et al., 2009), other studies
demonstrate that Aβ is not transported by BCRP (Hartz et al.,
2010; Krohn et al., 2011). Data from AD patient brain samples
are also conﬂicting: BCRP protein levels at the blood-brain barrier
have been reported to be unchanged (Wijesuriya et al., 2010), but
another study shows that BCRP expression is increased (Xiong
et al., 2009). The latter is contrary to what one would expect
if BCRP contributed to Aβ clearance from brain to blood. One
explanation that has been provided for increased BCRP in AD is
that it may act as a gatekeeper at the blood-brain barrier to pre-
vent Aβ from entering the brain (Xiong et al., 2009). However,
this is inconsistent with current knowledge of AD etiology indi-
cating that Aβ accumulation in the brain is not due to increased
Aβ uptake from the blood, but rather due to reduced Aβ clearance
from the brain.
Several issues could contribute to these conﬂicting ﬁndings.
For example, changes in transporter expression and/or activity
could depend on the AD model, patient or animal age, and/or
inter-individual differences between patients or research animals.
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Differences could also exist between AD in humans and modeled
AD in research animals. In addition, cell lines of non-brain ori-
gin may not accurately represent the in vivo blood-brain barrier
and provide a misleading assumption of BCRP expression and/or
activity in the brain. Clearly, future studies need to elucidate if
BCRP is involved in Aβ brain clearance and pathology. Answer-
ing this question will determine if BCRP could be a potential
therapeutic target in AD.
Future perspectives
An ideal AD medication corrects the pathophysiological cause of
AD, reverses, or at least halts, cognitive decline, prevents disease
onset, is effective in most patients with little side effects, and is
affordable.However, currently availableAD therapies have notmet
these criteria, and it is obvious that novel strategies are desperately
needed. Based on current knowledge, we propose that, under nor-
mal physiological conditions, Aβ clearance from the brain is, at
least in part, based on an interplay between ABCA1, LRP1, P-gp,
and MRP1 (and possibly BCRP; Figure 2). We postulate that a
decrease in function of ABCA1, LRP1, P-gp, or MRP1 (and possi-
bly BCRP),or a decrease in function of someor all of these proteins
reduces Aβ brain clearance, resulting in increased Aβ brain levels,
which may pose a risk for AD. Thus, one potential new strat-
egy that emerges from this picture is targeting ABC transporters
at the blood-brain barrier and in other CNS cells. However, this
approach is still in its infancy, and future research needs to address,
amongst others, the following basic questions:
(1) Do ABC transporters contribute to AD, and if so, what is the
contribution of each transporter?
FIGURE 2 | Based on current knowledge, we propose the following
interplay betweenAβ, ApoE,ABCA1, LRP1, P-gp, MRP1 (and possibly
BCRP): Under normal physiological conditions, ABCA1-mediated
cholesterol and phospholipid efflux from astrocytes, microglia, neurons
(and possibly endothelial cells) facilitates ApoE lipidation. Lipidated ApoE
associates with Aβ, and the ApoE-Aβ complex is taken up at the abluminal
membrane of the brain capillary endothelium; this step is facilitated by LRP1.
P-gp and MRP1 (and possibly BCRP) mediate Aβ efﬂux from the brain capillary
endothelium into the blood.We postulate that a decrease in function of either
ABCA1, LRP1, P-gp, or MRP1 (and possibly BCRP), or a decrease in function
of some or all of these proteins reduces Aβ brain clearance, resulting in
increased Aβ brain levels, which may pose a risk for AD.
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(2) How does AD affect ABC transporters in the CNS?
(3) Where do ABC transporters ﬁt in the larger “map” of AD
pathophysiology?
Answering these questions may still not bring us closer to a
viable strategy that can be translated into the clinic. And target-
ing ABC transporters alone may also be an ineffective approach.
Given the complexity of AD, it is unlikely to ﬁnd a “magic bullet.”
However, combining new strategies with existing ones that target
AD from different angles may increase the chance of ﬁnding an
effective therapy and may provide ﬂexible therapy modules for
individualized treatment tailored to patients’ needs.
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